DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1646-1659

  Wang, Yufeng ^a   Lei, Rong ^a   Zhuang, Xueqian ^a   Zhang, Ning ^b   Pan, Hong ^a   Li, Gang ^a   Hu, Jing ^a   Pan, Xiaoqi ^a   Tao, Qian ^c   Fu, Da ^a   Xiao, Jianru ^d   Chin, Y Eugene ^a   Kang, Yibin ^e   Yang, Qifeng ^b   Hu, Guohong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELETED IN LIVER CANCER 1 PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; P21 ACTIVATED KINASE 4; PARATHYROID HORMONE; PARATHYROID HORMONE LIKE HORMONE; PROTEIN CDC42; REGULATOR PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER CELL CULTURE; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CYTOSKELETON; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HORMONE INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TROPISM; TUMOR GROWTH;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; GTPASE-ACTIVATING PROTEINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OSTEOCLASTS; PARATHYROID HORMONE-RELATED PROTEIN; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEINS;

EID: 84897524474     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71812     Document Type: Article

References (65)

1. Hess KR, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624-1633.
2. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411-425.
3. Buijs JT, Stayrook KR, Guise TA. TGF-β in the bone microenvironment: role in breast cancer metastases. Cancer Microenviron. 2011;4(3):261-281.
4. Bierie B, Moses HL. Tumour microenvironment: TGF-β: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506-520. (Pubitemid 43980540)
5. Padua D, Massague J. Roles of TGF-β in metastasis. Cell Res. 2009;19(1):89-102.
6. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011;21(2):139-146.
7. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011;19(2):192-205.
8. Duivenvoorden WC, Hirte HW, Singh G. Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 1999;17(1):27-34. (Pubitemid 29284561)
9. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer. 1997;80(8 suppl):1572-1580. (Pubitemid 27444029)
10. Sit ST, Manser E. Rho GTPases and their role in organizing the actin cytoskeleton. J Cell Sci. 2011;124(pt 5):679-683.
11. Jeong KJ, et al. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene. 2012;31(39):4279-4289.
12. Vasiliev JM, Omelchenko T, Gelfand IM, Feder HH, Bonder EM. Rho overexpression leads to mitosis-associated detachment of cells from epithelial sheets: a link to the mechanism of cancer dissemination. Proc Natl Acad Sci U S A. 2004;101(34):12526-12530. (Pubitemid 39122057)
13. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2(2):133-142.
14. Tang Y, Olufemi L, Wang MT, Nie D. Role of Rho GTPases in breast cancer. Front Biosci. 2008;13:759-776. (Pubitemid 351599780)
15. Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol. 2008;40(5):843-847. (Pubitemid 351329658)
16. Kang Y, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537-549. (Pubitemid 36808649)
17. Minn AJ, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518-524. (Pubitemid 41112921)
18. Zhong D, et al. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci. 2009;122(pt 3):414-424.
19. Li G, Du X, Vass WC, Papageorge AG, Lowy DR, Qian X. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin focal adhesion kinase (FAK). Proc Natl Acad Sci U S A. 2011;108(41):17129-17134.
20. Iyer LM, Aravind L, Koonin EV. Common origin of four diverse families of large eukaryotic DNA viruses. J Virol. 2001;75(23):11720-11734. (Pubitemid 33063263)
21. Goto H, et al. Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. J Biol Chem. 1998;273(19):11728-11736. (Pubitemid 28272076)
22. Callow MG, et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem. 2002;277(1):550-558. (Pubitemid 34952091)
23. Healy KD, et al. DLC-1 suppresses non-small cell lung cancer growth invasion by RhoGAP-dependent independent mechanisms. Mol Carcinog . 2008;47(5):326-337. (Pubitemid 351614573)
24. Rajnicek AM, Foubister LE, McCaig CD. Temporally and spatially coordinated roles for Rho, Rac, Cdc42 and their effectors in growth cone guidance by a physiological electric field. J Cell Sci. 2006;119(pt 9):1723-1735. (Pubitemid 43810999)
25. Moorman JP, Luu D, Wickham J, Bobak DA, Hahn CS. A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival. Oncogene. 1999;18(1):47-57. (Pubitemid 29060578)
26. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-1664.
27. Padua D, et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66-77. (Pubitemid 351442989)
28. Roodman GD. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev. 2012;31(3-4):569-578.
29. Guise TA, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98(7):1544-1549. (Pubitemid 26327863)
30. Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell Signal. 2009;21(8):1245-1254.
31. Gallwitz WE, Guise TA, Mundy GR. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest. 2002;110(10):1559-1572. (Pubitemid 35396925)
32. Nissenson RA, Diep D, Strewler GJ. Synthetic peptides comprising the amino-terminal sequence of a parathyroid hormone-like protein from human malignancies. Binding to parathyroid hormone receptors and activation of adenylate cyclase in bone cells and kidney. J Biol Chem. 1988;263(26):12866- 12871.
33. Thota CS, Reed LC, Yallampalli C. Effects of parathyroid hormone like hormone (PTHLH) antagonist, PTHLH(7-34), on fetoplacental development growth during midgestation in rats. Biol Reprod. 2005;73(6):1191-1198. (Pubitemid 41698609)
34. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature. 2003;425(6958):577-584. (Pubitemid 37280136)
35. Wang G, Matsuura I, He D, Liu F. Transforming growth factor-β- inducible phosphorylation of Smad3. J Biol Chem. 2009;284(15):9663-9673.
36. Bae E, et al. Smad3 linker phosphorylation attenuates Smad3 transcriptional activity TGF-β1/Smad3-induced epithelial-mesenchymal transition in renal epithelial cells. Biochem Biophys Res Commun. 2012;427(3):593-599.
37. Sterling JA, et al. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression osteolysis in metastatic human breast cancer cells. Cancer Res. 2006;66(15):7548-7553. (Pubitemid 44289210)
38. Ying H, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 2006;5(9):2158-2164. (Pubitemid 44530451)
39. van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536.
40. Bos PD, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005-1009.
41. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
42. Sihto H, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 2011;13(5):R87.
43. Wong MH, Pavlakis N. Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press). 2011;3:35-60.
44. Ross DT, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24(3):227-235. (Pubitemid 30132189)
45. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 2009;69(13):5292-5293.
46. Goodison S, et al. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 2005;65(14):6042-6053. (Pubitemid 40994388)
47. Zhou X, et al. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and downregulation of genes involved in metastasis. Int J Oncol. 2008;32(6):1285-1291.
48. Henderson MA, et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res. 2006;66(4):2250-2256.
49. Henderson M, et al. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst. 2001;93(3):234-237. (Pubitemid 32166495)
50. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-273.
51. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev. 2006;25(4):521-529. (Pubitemid 46071861)
52. Massague J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616-630.
53. Mardilovich K, Olson MF, Baugh M. Targeting Rho GTPase signaling for cancer therapy. Future Oncol. 2012;8(2):165-177.
54. Micuda S, Rosel D, Ryska A, Brabek J. ROCK inhibitors as emerging therapeutic candidates for sarcomas. Curr Cancer Drug Targets. 2010;10(2):127-134.
55. Ruppender NS, et al. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One. 2010;5(11):e15451.
56. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res. 2009;69(22):8742-8751.
57. Martin TJ. Manipulating the environment of cancer cells in bone: a novel therapeutic approach. J Clin Invest. 2002;110(10):1399-1401. (Pubitemid 35396908)
58. Winklmayr M, et al. Non-consensus GLI binding sites in Hedgehog target gene regulation. BMC Mol Biol. 2010;11:2.
59. Korpal M, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15(8):960-966.
60. Acharya PS, et al. Fibroblast migration is mediated by CD44-dependent TGF beta activation. J Cell Sci. 2008;121(pt 9):1393-1402. (Pubitemid 351936304)
61. Lei R, et al. Suppression of MIM by microRNA-182 activates RhoA promotes breast cancer metastasis [published online ahead of print March 11, 2013]. Oncogene. doi:10.1038/onc.2013.65.
62. Mak IW, et al. PTHrP induces autocrine/paracrine proliferation of bone tumor cells through inhibition of apoptosis. PLoS One. 2011;6(5):e19975.
63. Sherafat-Kazemzadeh R, Schroeder JK, Kessler CA, Handwerger S. Parathyroid hormone-like hormone (PTHLH) represses decidualization of human uterine fibroblast cells by an autocrine/paracrine mechanism. J Clin Endocrinol Metab. 2011;96(2):509-514.
64. Nelson JD, Denisenko O, Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc. 2006;1(1):179-185.
65. Hu G, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance metastasis of poor-prognosis breast cancer. Cancer Cell. 2009;15(1):9-20.